Table 1.

Clinicopathologic features of BRAF alterations in high grade colorectal neuroendocrine tumors.

Case	Age	Sex	Tumor Location	Stage, Grade	KRAS, APC Status	BRAF Event	Tumor Purity (%)	BRAF MAF (%)	BRAF Coverage	Sample Coverage	Response to BRAF-i
1*	70	F	Rectum	IV, 3	KRAS: WT APC: WT	V600E	59	26	463	529	Yes
2	39	F	Rectum	IV, 3	KRAS: WT APC: WT	V600E	49	53	734	647	Yes
3	64	M	Rectum	IV, 3	KRAS: WT APC: R1114* APC: V1414fs*1	G469A	80	55	1446	904	N/A
4	66	M	Colon	IV, 2	KRAS: G12S APC: WT	V600E	36	1	402	459	N/A
5	51	F	Colon	IV, 3	KRAS: WT APC: R554* APC: Q1541*	V600E	30	31	372	445	N/A
6	62	M	Colon	IV, 3	KRAS: WT APC: WT	V600E	78	54	1079	596	N/A
7	78	M	Rectum	IV, 3	KRAS: WT APC: WT	V600E	60	34	612	430	N/A
8	45	F	Colon	IV, 3	KRAS: WT APC: WT	V600E	66	42	587	436	N/A
9	70	M	Colon	IV, 2	KRAS: A146T APC: R1450*	R671Q	30	44	636	612	N/A
10	69	F	Rectum	IV, 3	KRAS: WT APC: WT	V600E	19	9	552	575	N/A

Abbreviations: F; female, M; male, MAF; mutant allele frequency, WT; wild type, N/A; data not available.

Asterisk (*) represents the incident case, case 1.